Literature DB >> 8354303

Comparison of fixed concentration and fixed ratio options for dilution susceptibility testing of gram-negative bacilli to ampicillin and ampicillin/sulbactam.

M A Pfaller1, A L Barry, P C Fuchs, E H Gerlach, D J Hardy, J C McLaughlin.   

Abstract

Ampicillin combined with sulbactam was tested at both fixed ratio (2:1 and 1:1) and fixed sulbactam concentrations (4 micrograms/ml, 8 micrograms/ml and 16 micrograms/ml) against 2440 consecutively isolated gram-negative bacilli. Sulbactam significantly enhanced the spectrum of ampicillin activity. Overall, at 8 micrograms/ml ampicillin inhibited 50% of the Enterobacteriaceae isolates, whereas 69% to 84% of the isolates were inhibited by the various sulbactam combinations. The widest spectrum of activity for ampicillin/sulbactam was achieved by testing at a fixed sulbactam concentration of 16 micrograms/ml, followed by the 1:1 ratio and the fixed 8 micrograms/ml (84%, 76% and 74% inhibited, respectively). The amount of sulbactam at the susceptible breakpoint concentrations of ampicillin markedly affected the percentage of susceptible strains. Combinations that include 8 micrograms/ml of sulbactam are suggested for consideration.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8354303     DOI: 10.1007/bf01964434

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   3.267


  11 in total

1.  In vitro activity of sulbactam in combination with various beta-lactam antibiotics.

Authors:  J Klastersky; P Van der Auwera
Journal:  Diagn Microbiol Infect Dis       Date:  1989 Jul-Aug       Impact factor: 2.803

2.  CP-45,899, a beta-lactamase inhibitor that extends the antibacterial spectrum of beta-lactams: initial bacteriological characterization.

Authors:  A R English; J A Retsema; A E Girard; J E Lynch; W E Barth
Journal:  Antimicrob Agents Chemother       Date:  1978-09       Impact factor: 5.191

3.  Optimal dilution susceptibility testing conditions, recommendations for MIC interpretation, and quality control guidelines for the ampicillin-sulbactam combination.

Authors:  R N Jones; A L Barry
Journal:  J Clin Microbiol       Date:  1987-10       Impact factor: 5.948

4.  Sulbactam plus ampicillin: interim review of efficacy and safety for therapeutic and prophylactic use.

Authors:  L Lees; J A Milson; A K Knirsch; K Greenhalgh
Journal:  Rev Infect Dis       Date:  1986 Nov-Dec

Review 5.  Pharmacokinetics of sulbactam/ampicillin in humans: a review.

Authors:  G Foulds
Journal:  Rev Infect Dis       Date:  1986 Nov-Dec

6.  Sulbactam/ampicillin: in vitro spectrum, potency, and activity in models of acute infection.

Authors:  J A Retsema; A R English; A Girard; J E Lynch; M Anderson; L Brennan; C Cimochowski; J Faiella; W Norcia; P Sawyer
Journal:  Rev Infect Dis       Date:  1986 Nov-Dec

7.  Comparative activities of the beta-lactamase inhibitors YTR 830, clavulanate, and sulbactam combined with ampicillin and broad-spectrum penicillins against defined beta-lactamase-producing aerobic gram-negative bacilli.

Authors:  M R Jacobs; S C Aronoff; S Johenning; D M Shlaes; S Yamabe
Journal:  Antimicrob Agents Chemother       Date:  1986-06       Impact factor: 5.191

8.  In vitro evaluations of aminopenicillin/beta-lactamase inhibitor combinations.

Authors:  R N Jones
Journal:  Drugs       Date:  1988       Impact factor: 9.546

9.  Comparative activities of the beta-lactamase inhibitors YTR 830, sodium clavulanate, and sulbactam combined with amoxicillin or ampicillin.

Authors:  S C Aronoff; M R Jacobs; S Johenning; S Yamabe
Journal:  Antimicrob Agents Chemother       Date:  1984-10       Impact factor: 5.191

10.  Sulbactam/ampicillin versus metronidazole/gentamicin in the treatment of post-cesarean section endometritis.

Authors:  M G Martens; S Faro; H A Hammill; D Smith; G Riddle; M Maccato
Journal:  Diagn Microbiol Infect Dis       Date:  1989 Jul-Aug       Impact factor: 2.803

View more
  8 in total

1.  A Systematic Approach to the Selection of the Appropriate Avibactam Concentration for Use with Ceftazidime in Broth Microdilution Susceptibility Testing.

Authors:  Patricia A Bradford; Michael D Huband; Gregory G Stone
Journal:  Antimicrob Agents Chemother       Date:  2018-06-26       Impact factor: 5.191

2.  Multilaboratory testing of antifungal drug combinations against Candida species and Aspergillus fumigatus: utility of 100 percent inhibition as the endpoint.

Authors:  Ping Ren; Ming Luo; Shao Lin; Mahmoud A Ghannoum; Nancy Isham; Dan J Diekema; Michael A Pfaller; Shawn Messer; Shawn R Lockhart; Naureen Iqbal; Vishnu Chaturvedi
Journal:  Antimicrob Agents Chemother       Date:  2014-12-15       Impact factor: 5.191

3.  In Vitro Evaluation of Antifungal Drug Combinations against Multidrug-Resistant Candida auris Isolates from New York Outbreak.

Authors:  Brittany O'Brien; Sudha Chaturvedi; Vishnu Chaturvedi
Journal:  Antimicrob Agents Chemother       Date:  2020-03-24       Impact factor: 5.191

Review 4.  New β-Lactam-β-Lactamase Inhibitor Combinations.

Authors:  Dafna Yahav; Christian G Giske; Alise Grāmatniece; Henrietta Abodakpi; Vincent H Tam; Leonard Leibovici
Journal:  Clin Microbiol Rev       Date:  2020-11-11       Impact factor: 26.132

5.  Pharmacodynamics of ampicillin-sulbactam in an in vitro infection model against Escherichia coli strains with various levels of resistance.

Authors:  K C Lamp; M K Vickers
Journal:  Antimicrob Agents Chemother       Date:  1998-02       Impact factor: 5.191

6.  Ampicillin-sulbactam susceptibility testing criteria.

Authors:  A Barry; M Pfaller; P Fuchs; E Gerlach; D Hardy; J McLaughlin
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1993-06       Impact factor: 3.267

Review 7.  What the Clinical Microbiologist Should Know About Pharmacokinetics/Pharmacodynamics in the Era of Emerging Multidrug Resistance: Focusing on β-Lactam/β-Lactamase Inhibitor Combinations.

Authors:  Henrietta Abodakpi; Audrey Wanger; Vincent H Tam
Journal:  Clin Lab Med       Date:  2019-07-06       Impact factor: 1.935

8.  Ampicillin-sulbactam and amoxicillin-clavulanate susceptibility testing of Escherichia coli isolates with different beta-lactam resistance phenotypes.

Authors:  A Oliver; M Pérez-Vázquez; M Martínez-Ferrer; F Baquero; L De Rafael; R Cantón
Journal:  Antimicrob Agents Chemother       Date:  1999-04       Impact factor: 5.191

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.